---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-004182"
form_type: "8-K"
ticker: null
cik: "0001496671"
company_name: "Calithera Biosciences, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:44:20.319073+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Calithera Biosciences board approves complete liquidation; common stockholders expected to receive no distributions

## Summary
- Board unanimously approved dissolution and liquidation, subject to stockholder approval; special meeting in Q1 2023.
- Reduction-in-force of substantially all employees; estimated $8M in severance and related charges.
- CEO Susan Molineaux, CFO Stephanie Wong, and SVP Eric Sjogren to depart; CFO receives $100K retention bonus for wind-down.
- All clinical programs discontinued; Company does not expect any liquidating distributions to common stockholders due to Series A preferred liquidation preference.
- Plan to delist from Nasdaq, file certificate of dissolution upon approval, and satisfy remaining liabilities.

## SEC filing metadata
- accession: 0001193125-23-004182
- form_type: 8-K
- cik: 0001496671
- company_name: Calithera Biosciences, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/d406710d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-004182
- JSON: https://secwatch.observer/filing/0001193125-23-004182.json
- Plain text: https://secwatch.observer/filing/0001193125-23-004182.txt

## Key facts
- Executive change
  Stephanie Wong departed as Chief Financial Officer at Calithera Biosciences, Inc..
  - Action: will also be leaving
  - Role: Chief Financial Officer
  source text: Susan M. Molineaux, Ph.D., our President and Chief Executive Officer, and Stephanie Wong, our Chief Financial Officer, will also be leaving Calithera Biosciences as of future date to be determined
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm
- Executive change
  Eric Sjogren departed as Senior Vice President, Drug Discovery at Calithera Biosciences, Inc..
  - Action: will be leaving
  - Role: Senior Vice President, Drug Discovery
  source text: Eric Sjogren, Ph.D. our Senior Vice President, Drug Discovery will be leaving Calithera Biosciences on February 3, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm
- Executive change
  Susan M. Molineaux departed as President and Chief Executive Officer at Calithera Biosciences, Inc..
  - Action: will also be leaving
  - Role: President and Chief Executive Officer
  source text: Susan M. Molineaux, Ph.D., our President and Chief Executive Officer, and Stephanie Wong, our Chief Financial Officer, will also be leaving Calithera Biosciences as of future date to be determined
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm
- Restructurings & Charges
  Calithera Biosciences, Inc. announced a restructuring with charges of approximately $8 million affecting Calithera Biosciences, Inc. (complete dissolution) (reduction-in-force of substantially all our employees, including our executive officers).
  - Type: restructuring
  - Charge: approximately $8 million
  - Affected area: Calithera Biosciences, Inc. (complete dissolution)
  - Headcount: reduction-in-force of substantially all our employees, including our executive officers
  source text: We estimate that we will incur charges of approximately $8 million in connection with the reduction-in-force, primarily consisting of severance payments, notice pay (where applicable), employee benefits contributions and related costs.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496671/000119312523004182/0001193125-23-004182-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.